Business
Vetoquinol: 2025 Annual Sales
LURE, France, January 29, 2026--Regulatory News: In an economy marked by unusual exchange rate volatility, Vetoquinol (Paris:VETO) achieved two important objectives: growth in Essential products and internalization of the manufacturing of the parasiticide range.
About this update from Vetoquinol Sa
[{"type":"text","content":"Annual sales: €526 million (up 0.2% at constant exchange rates and down 2.5% on a reported basis)","length":97,"tagName":"p"},{"type":"text","content":"Annual sales of Essential Products: €334 million (up 4.1% at constant exchange rates and up 2.1% on a reported basis)","length":117,"tagName":"p"},{"type":"text","content":"LURE, France, January 29, 2026--(BUSINESS WIRE)--Regulatory News:","length":65,"tagName":"p"},{"type":"text","content":"In an economy marked by unusual exchange rate volatility, Vetoquinol (Paris:VETO) achieved two important objectives: growth in Essential products and internalization of the manufacturing of the parasiticide range.","length":213,"tagName":"p"},{"type":"text","content":"Vetoquinol's sales for FY 2025 came to €525.7 million, up 0.2% at constant exchange rates and down 2.5% on a reported basis. Over the financial year, the company recorded historically high negative currency impacts of €14.8 million in all territories except Europe and a significant impact from the simplification of the Complementary product ranges of -€9.7 million. Net of these two items, sales for the 2025 financial year were up 2.1% compared with 2024.","length":462,"tagName":"p"},{"type":"text","content":"Sales of Essential Products totaled €334.5 million, up 4.1% at constant exchange rates and 2.1% on a reported basis. This growth was driven by a strong 4th quarter, which saw Essential Products rise by 8.0% at constant exchange rates, correcting the gap at the end of September linked to the completion of transfers to the Group's plants of the manufacture of the parasiticide products acquired in 2020. These transfers are now complete. Essential products accounted for 64% of the Group’s sales for the 2025 financial year, compared with 61% for the 2024 financial year.","length":575,"tagName":"p"},{"type":"text","content":"Sales in Europe for fiscal year 2025 amounted to €259.4 million. Excluding the Complementary product range simplification program, sales were driven by the momentum of Essential products. The United States ended the year with growth of 0.4% at constant exchange rates. The Americas region excluding the United States declined by 1.5% at constant exchange rates. The Asia-Pacific/Rest of the World region recorded solid growth of 7.6% at constant exchange rates.","length":461,"tagName":"p"},{"type":"text","...